Literature DB >> 31462556

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.

Yupei Zhao1,2, Kui Wu3,4, Wenming Wu1, Xiafei Hong5, Sitan Qiao6,4, Fuqiang Li6,4, Wenze Wang7, Rui Jiang5, Huanwen Wu7, Hao Chen5, Lulu Liu8, Junya Peng8, Jing Wang7, Congwei Jia7, Xiaolong Liang7, Hongmei Dai5, Jialin Jiang5, Taiping Zhang5, Quan Liao5, Menghua Dai5, Lin Cong5, Xianlin Han5, Dan Guo8,9, Zhiyong Liang7, Dongjing Li10, Zetian Zheng6,4, Chen Ye6,4, Siliang Li6,4.   

Abstract

OBJECTIVE: Insulinomas and non-functional pancreatic neuroendocrine tumours (NF-PanNETs) have distinctive clinical presentations but share similar pathological features. Their genetic bases have not been comprehensively compared. Herein, we used whole-genome/whole-exome sequencing (WGS/WES) to identify genetic differences between insulinomas and NF-PanNETs.
DESIGN: The mutational profiles and copy-number variation (CNV) patterns of 211 PanNETs, including 84 insulinomas and 127 NF-PanNETs, were obtained from WGS/WES data provided by Peking Union Medical College Hospital and the International Cancer Genome Consortium. Insulinoma RNA sequencing and immunohistochemistry data were assayed.
RESULTS: PanNETs were categorised based on CNV patterns: amplification, copy neutral and deletion. Insulinomas had CNV amplifications and copy neutral and lacked CNV deletions. CNV-neutral insulinomas exhibited an elevated rate of YY1 mutations. In contrast, NF-PanNETs had all three CNV patterns, and NF-PanNETs with CNV deletions had a high rate of loss-of-function mutations of tumour suppressor genes. NF-PanNETs with CNV alterations (amplification and deletion) had an elevated risk of relapse, and additional DAXX/ATRX mutations could predict an increased relapse risk in the first 2-year period.
CONCLUSION: These WGS/WES data allowed a comprehensive assessment of genetic differences between insulinomas and NF-PanNETs, reclassifying these tumours into novel molecular subtypes. We also proposed a novel relapse risk stratification system using CNV patterns and DAXX/ATRX mutations. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gene mutation; neuroendocrine tumours; pancreas

Year:  2019        PMID: 31462556     DOI: 10.1136/gutjnl-2018-317233

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

Review 1.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

Review 3.  [Modern molecular and imaging diagnostics in pancreatic neuroendocrine neoplasms].

Authors:  Costanza Chiapponi; Christiane J Bruns
Journal:  Chirurgie (Heidelb)       Date:  2022-05-25

4.  Artificial intelligence - upping the game in gastrointestinal endoscopy?

Authors:  Colin J Rees; Sara Koo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10       Impact factor: 46.802

5.  Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.

Authors:  Oleg I Kit; Vladimir S Trifanov; Nataliya A Petrusenko; Dmitry Y Gvaldin; Denis S Kutilin; Nataliya N Timoshkina
Journal:  Mol Biol Rep       Date:  2020-05-25       Impact factor: 2.742

6.  Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.

Authors:  Wenzel M Hackeng; Willemien Schelhaas; Folkert H M Morsink; Charlotte M Heidsma; Susanne van Eeden; Gerlof D Valk; Menno R Vriens; Christopher M Heaphy; Els J M Nieveen van Dijkum; G Johan A Offerhaus; Koen M A Dreijerink; Lodewijk A A Brosens
Journal:  Endocr Pathol       Date:  2020-06       Impact factor: 3.943

7.  Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors.

Authors:  Barish H Edil; Wenyi Luo; Min Li
Journal:  BMC Med       Date:  2020-07-08       Impact factor: 8.775

8.  Comprehensive Analysis of Copy Number Variations in Kidney Cancer by Single-Cell Exome Sequencing.

Authors:  Wenyang Zhou; Fan Yang; Zhaochun Xu; Meng Luo; Pingping Wang; Yu Guo; Huan Nie; Lifen Yao; Qinghua Jiang
Journal:  Front Genet       Date:  2020-01-23       Impact factor: 4.599

9.  Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma.

Authors:  Vania Balderrama Brondani; Amanda Meneses Ferreira Lacombe; Beatriz Marinho de Paula Mariani; Luciana Montenegro; Iberê Cauduro Soares; João Evangelista Bezerra-Neto; Fabio Yoshiaki Tanno; Victor Srougi; José Luis Chambo; Berenice Bilharinho Mendonca; Madson Q Almeida; Maria Claudia Nogueira Zerbini; Maria Candida Barisson Villares Fragoso
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

10.  An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.

Authors:  Hua Liu; Rongli Xie; Zhifeng Zhao; Dan Xu; Kaige Yang; Min Ding; Dan Tan; Wenqiang Liao; Xujie Han; Jun Zhang; Dongjie Shen; Jianmin Yuan; Zhiwei Xu; Jian Fei
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.